Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Sales of AbbVie's Humira are plummeting as the once-top-selling drug fights ...
Shares of AbbVie (NYSE:ABBV) were down 6% in afternoon trading Friday in the wake of the drugmaker's Q1 earnings report and news that Cigna (CI) plans to offer a biosimilar of AbbVie’s top-selling ...
AbbVie has delivered strong YTD outperformance, with shares up nearly 30% and robust analyst optimism, but I maintain a 'Hold ...
April 26 (Reuters) - AbbVie (ABBV.N), opens new tab expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen after recent changes by U.S. pharmacy benefit managers and as ...
AbbVie posted first-quarter results largely as projected, and we don’t expect any major changes to our fair value estimate. With the arrival of the first U.S. biosimilar to Humira, AbbVie’s results ...
Although Humira sales continue to fall as the drug faces biosimilar competition, AbbVie raised its profit outlook for this year and next as demand grows for its newer immunology drugs. The North ...
AbbVie Inc. raised its profit outlook for this year and next as demand for newer biologic drugs helped fill the gap left by falling Humira sales, but investors were disappointed as Botox sales missed ...
NEW YORK, Jan 27 (Reuters) - Abbott Laboratories reported stronger-than-expected fourth-quarter results, helped by lower taxes and reduced expenses, but weak U.S. sales of its Humira arthritis drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback